Primary prophylactic human papillomavirus vaccination programs: Future perspective on global impact

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 627-639

  Brotherton, Julia M L ^a,b   Gertig, Dorota M ^a  

^a VICTORIAN CYTOLOGY SERVICE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cervical cancer prevention; cervical intraepithelial neoplasia; cervical screening; genital warts; HPV DNA; human papillomavirus vaccination; vaccine safety; vaccine surveillance

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER CONTROL; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GUILLAIN BARRE SYNDROME; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOSURVEILLANCE; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTERPERSONAL COMMUNICATION; MULTIPLE SCLEROSIS; MYALGIA; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; REVIEW; SYNCOPE; THROMBOEMBOLISM; TUMOR VOLUME; UTERINE CERVIX CANCER;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SAFETY; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 80051775549     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.78     Document Type: Review

References (138)

1. Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology 34, 213-224 (2002). (Pubitemid 34628180)
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401, 70-29 (2010).
3. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect. Agents Cancer 4, 8 (2009).
4. Bouvard V, Baan R, Straif K et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol. (4), 321-322 (2009).
5. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer 21, 621-632 (2007). (Pubitemid 46986496)
6. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048-1056 (2010).
7. Garland SM, Steben M, Sings HL et al. Natural history of genital warts: Analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 199(6), 805-814 (2009).
8. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: A review. Laryngoscope 118, 1236-1247 (2008).
9. Syrjanen K, Hakama M, Saarikoski S et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex. Transm. Dis. 17, 15-19 (1990). (Pubitemid 20110405)
10. Giuliano AR, Lee JH, Fulp W et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 377(9769), 932-940 (2011).
11. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: A global review. J. Adolesc. Health 43(4 Suppl.), S5-S25 (2008).
12. Barnabas RV, Laukkanen P, Koskela P et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses. PLoS Med. 3, e138 (2006).
13. Burchell AN, Tellier PP, Hanley J, Coutlée F, Franco EL. Human papillomavirus infections among couples in new sexual relationships. Epidemiology 21(1), 31-37 (2010).
14. Stanley M. HPV: Immune response to infection and vaccination. Infect. Agents Cancer 5, 19 (2010).
15. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J. Natl Cancer Inst. Monogr. 31, 3-13 (2003).
16. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: Novel functions of E6 and E7 oncoproteins. Rev. Med. Virol. 19(2), 97-113 (2009).
17. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 89, 213-228 (2002). (Pubitemid 35351540)
18. International Collaboration of Epidemiological Studies of Cervical Cancer (ICESCC). Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int. J. Cancer 118, 1481-1495 (2006).
19. Smith JS, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl Cancer Inst. 94(21), 1604-1613 (2002). (Pubitemid 35378725)
20. Smith JS, Bosetti C, Muñoz N et al. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int. J. Cancer 111(3), 431-439 (2004). (Pubitemid 38998826)
21. International Collaboration of Epidemiological Studies of Cervical Cancer; Appleby P, Beral V et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599), 1609-1621 (2007).
22. International Collaboration of Epidemiological Studies of Cervical Cancer (ICESCC). Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int. J. Cancer 119(5), 1108-1124 (2006).
23. Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J. Natl Cancer Inst. Monogr. 31, 41-46 (2003).
24. World Health Organization. Control of cancer of the cervix uteri. A WHO meeting. Bull. World Health Organ. 64, 607-618 (1986).
25. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287, 2114-2119 (2002). (Pubitemid 34437346)
26. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 370, 890-907 (2007). (Pubitemid 47371147)
27. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. Br. J. Cancer 91, 530-536 (2004). (Pubitemid 39093574)
28. Bos AB, van Ballegooijen M, van Oortmarssen GJ, van Marle ME, Habbema JD, Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br. J. Cancer 75, 124-130 (1997). (Pubitemid 27007284)
29. van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br. J. Cancer 64, 559-565 (1991).
30. Laara E, Day N, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes. Lancet 1(8544), 1247-1249 (1987). (Pubitemid 17070815)
31. Cancer of the cervix: Death by incompetence. Lancet 2 (8451), 363-364 (1985).
32. Pirotta M, Ung L, Stein A et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex. Transm. Infect. 85(7), 508-513 (2009).
33. McCaffery KJ, Irwig L, Turner R et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: An open randomised trial. BMJ 23(340), b4491 (2010).
34. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E. Psychological response to cervical screening. Prev. Med. 24(6), 610-616 (1995).
35. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet. Gynecol. 109, 309-313 (2007). (Pubitemid 46197421)
36. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 367, 489-498 (2006). (Pubitemid 43208905)
37. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113, 3036-3046 (2008).
38. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications, Lyon, France, No. 160 (2007).
39. Daling JR, Weiss NS, Hislop TG et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N. Engl. J. Med. 317, 973-977 (1987). (Pubitemid 17147952)
40. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370, 59-67 (2007). (Pubitemid 47017468)
41. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 21, S3/35-S3/41 (2006).
42. Woodhall SC, Jit M, Cai C et al. Cost of treatment and QALYs lost due to genital warts: Data for the economic evaluation of HPV vaccines in the United Kingdom. Sex. Transm. Dis. 36(8), 515-512 (2009).
43. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185(1), 251-257 (1991).
44. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89(24), 12180-12184 (1992). (Pubitemid 23004809)
45. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67(1), 315-322 (1993). (Pubitemid 23002992)
46. Block SL, Nolan T, Sattler C et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118, 2135-2145 (2006). (Pubitemid 46393698)
47. Romanowski B, de Borba PC, Naud PS et al. ; GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374(9706), 1975-1985 (2009).
48. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
49. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. FUTURE I Investigators. N. Engl. J. Med. 356, 1928-1943 (2007). (Pubitemid 46740303)
50. FUTURE I/II Study Group, Dillner J, Kjaer SK et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 341, c3493 (2010).
51. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369(9574), 1693-1702 (2007). (Pubitemid 46783792)
52. Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369(9576), 1861-1868 (2007). (Pubitemid 46829356)
53. Muñoz N, Manalastas R Jr, Pitisuttithum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373(9679), 1949-1957 (2009).
54. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364 (5), 401-411 (2011).
55. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009). This analysis of just under 20,000 women participating in the bivalent HPV vaccine trial found very high efficacy against high-grade cervical disease due to HPV16/18 among women previously uninfected with those types (93%).
56. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199(7), 926-935 (2009).
57. Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5(10), 705-719 (2009).
58. De Carvalho N, Teixeira J, Roteli-Martins CM et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28(38), 6247-6255 (2010).
59. Kjaer SK, Sigurdsson K, Iversen OE et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila.) 2(10), 868-878 (2009).
60. Rowhani-Rahbar A, Mao C, Hughes JP et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27(41), 5612-5619 (2009).
61. Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25(26), 4931-4939 (2007). (Pubitemid 46843434)
62. Moscicki B et al. Anamnestic response elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in young women. Presented at: European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.
63. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179(6), 525-533 (2008).
64. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302(7), 750-757 (2009).
65. Crawford NW, Clothier HJ, Elia S, Lazzaro T, Royle J, Buttery JP. Syncope and seizures following human papillomavirus vaccination: A retrospective case series. Med. J. Aust. 194 (1), 16-18 (2011).
66. World Health Organisation. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol. Rec. 32 (84), 325-332 (2009).
67. Wacholder S, Chen BE, Wilcox A et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials. BMJ 340, c712 (2010).
68. Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: A combined analysis of five randomized controlled trials. Obstet. Gynecol. 114(6), 1179-1188 (2009).
69. World Health Organisation. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol. Rec. 84, 118-130 (2009).
70. Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298(7), 743-753 (2007). (Pubitemid 47263157)
71. Lévy-Bruhl D, Bousquet V, King LA et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey. Eur. J. Cancer 45(15), 2709-2713 (2009).
72. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sexual Health 7, 352-358 (2010).
73. Skinner SR, Cooper Robbins SC. Voluntary school-based human papillomavirus vaccination: An efficient and acceptable model for achieving high vaccine coverage in adolescents. J. Adolesc. Health 47(3), 215-218 (2010).
74. Kreimer AR, Rodriguez AC, Hildesheim A et al. Proof-of-principle: Efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica. Presented at: 26th International Papillomavirus Conference. Montreal, Canada, 3-8 July 2010.
75. Krajden M, Cook D, Yu A et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin. Vaccine Immunol. 18(3), 418-423 (2011).
76. Zhou F, Santoli J, Messonnier ML et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch. Pediatr. Adolesc. Med. 159(12), 1136-1144 (2005). (Pubitemid 41758633)
77. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26(32), 4080-4093 (2008). Modeled the cost-effectiveness of HPV vaccination in 72 low-resource countries under different scenarios and found that provided high coverage of young adolescent girls is feasible, and vaccine costs are lowered, HPV16/18 vaccination could be very cost effective even in the poorest countries.
78. Haas M, Ashton T, Blum K et al. Drugs, sex, money and power: An HPV vaccine case study. Health Policy 92(2-3), 288-295 (2009).
79. Ferris DG, Cromwell L, Waller JL, Horn L. Most parents do not think receiving human papillomavirus vaccine would encourage sexual activity in their children. J. Low. Genit. Tract Dis. 14(3), 179-184 (2010).
80. Marlow LAV, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J. Adolesc. Health 44, 446-451 (2009).
81. Marlow LAV, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine 25, 1945-1952 (2007). (Pubitemid 46227684)
82. Marshall H, Ryan P, Robertson D, Baghurst P. A cross sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust. NZ J. Public Health 31, 235-242 (2007). (Pubitemid 47078660)
83. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 28(9), 2070-2075 (2010).
84. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, McCann R. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: Prospective cohort study. BMJ 336, 1056-1058 (2008). (Pubitemid 351692248)
85. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: A representative statewide analysis. J. Adolesc. Health 40, 108-115 (2007). (Pubitemid 46149373)
86. Conroy K, Rosenthal SL, Zimet GD et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. Journal of Women's Health 18(10), 1679-1686 (2009).
87. Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: Uptake and intentions. J. Adolesc. Health 45, 528-531 (2009).
88. Mathur MB, Mathur VS, Reichling DB. Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status. J. Pediatr. Health Care 24, 14-24 (2010).
89. Gottlieb SL, Brewer NT, Sternberg MR et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J. Adolesc. Health 45(5), 430-437 (2009).
90. Centers for Disease Control and Prevention (CDC). National, State, and Local area vaccination coverage among adolescents aged 13- 17 years - United States, 2009. Morb. Mort. Wkly Rep. 59 (32), 1018-1023 (2010).
91. Lindley MC, Shen AK, Orenstein WA et al. Financing the delivery of vaccines to children and adolescents: Challenges to the current system. Pediatrics 124, S548-S557 (2009).
92. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: Results of a national survey. J. Adolesc. Health 45, 453-462 (2009).
93. Reiter PL, Brewer NT, Gottleib SL, McRee AL, Smith JS. Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc. Sci. Med. 69,475-480 (2009).
94. Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol. Biomarkers Prev. 18(2), 363-372 (2009).
95. Ogilvie G, Anderson M, Marra F et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: Parental factors associated with HPV vaccine receipt. PLoS Med. 7(5), e1000270 (2010).
96. Agius PA, Pitts MK, Smith AM, Mitchell A. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 28(27), 4416-4422 (2010).
97. Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Skinner SR. "Is cancer contagious?": Australian adolescent girls and their parents: Making the most of limited information about HPV and HPV vaccination. Vaccine 28(19), 3398-3408 (2010).
98. Cooper Robbins SC, Bernard D, McCaffery K, Brotherton JML, Skinner SR. "I just signed": Factors influencing decision making for school-based HPV vaccination. Health Psychology 29, 618-625 (2010).
99. MacDonald P. Country experiences with HPV vaccine introduction: United Kingdom. Presented at: The First Symposium on Human Papillomavirus Vaccination in the Asia-Pacific and Middle East Regions. Seoul, Korea, 1-2 June 2009.
100. Bowring J, Walker P. The "Jade Goody effect': What now for cervical cancer prevention? J. Fam. Plann. Reprod. Health Care 36(2), 51-54 (2010).
101. Naismith S. Taking the service to the young people: A study and analysis of a clinic specifically set up for HPV vaccination provision. J. Fam. Plann. Reprod. Health Care 35(4), 262-263 (2009).
102. Wong LP. HPV information needs, educational messages and channel of delivery preferences: Views from developing country with multi-ethnic populations. Vaccine 27, 1410-1415 (2009).
103. Russell F, Bingwor F. Country experiences with HPV vaccine introduction: Fiji. Presented at: The First Symposium on Human Papillomavirus Vaccination in the Asia-Pacific and Middle East Regions. Seoul, Korea, 1-2 June 2009.
104. WHO, UNICEF, World Bank. State of the World's Vaccines and Immunization, 3rd Edition. WHO, Geneva, Switzerland (2009).
105. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust. NZ J. Public Health 33(4), 365-370 (2009).
106. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet 376(9741), 572-573 (2010).
107. Bonanni P, Cohet C, Kjaer SK et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®. Vaccine 28, 4719-4730 (2010).
108. Brotherton JML, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: Towards a national HPV surveillance strategy. Sexual Health 7(3), 310-319 (2010).
109. Wong CA, Saraiya M, Hariri S et al. Approaches to monitoring biological outcomes for HPV vaccination: Challenges of early adopter countries. Vaccine 29(5), 878-885 (2010).
110. WHO. Report of the meeting on HPV Vaccine Coverage and Impact Monitoring 16-17 November 2009. Department of Immunization, Vaccines and Biologicals, WHO, Geneva, Switzerland, WHO/IVB/10.05 (2010).
111. Smith M, Canfell K, Brotherton J, Lew J-B, Barnabas R; on behalf of the Modellers Sans Frontières working group. The predicted impact of vaccination on human papillomavirus infections in Australia. Int. J. Cancer 123(8), 1854-1863 (2008).
112. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br. J. Cancer 102, 933-939 (2010).
113. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 26(Suppl. 10), K76-K86 (2008).
114. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV 16,18 vaccine for cervical cancer prevention in developing countries: Policy implications. Reprod. Health Matters 16, 86-96 (2008).
115. Diaz M, Kim JJ, Albero G et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br. J. Cancer 99(2), 230-238 (2008).
116. Goldie SJ, Kim JJ, Kobus K et al. Cost-effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 25, 6257-6270 (2007). (Pubitemid 47088030)
117. Cameron JE, Hagensee ME. Human papillomavirus infection and disease in the HIV+ individual. Cancer Treat. Res. 133, 185-213 (2007).
118. Levin M, Moscicki A-B, Song L-Y et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J. AIDS 55(2), 197-204 (2010).
119. Wilkin T, Lee JY, Lensing SY et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 202 (8), 1246-1253 (2010).
120. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 24, S3/140-S3/146 (2006).
121. Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect. Dis. 11(1), 39-44 (2011).
122. Brotherton JML, Fridman M, May C, Chappell G, Saville AM, Gertig DM. Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 377, 2085-2092 (2011).
123. Garnett GP, Kim JJ, French K, Goldie SJ. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24, S3/178-S3/186 (2006).
124. Bach PB. Gardasil: From bench, to bedside, to blunder. Lancet 375, 963-964 (2010).
125. Desai S, Soldan K, White J, Sheridan A, Gill ON. Human papillomavirus vaccine coverage [letter]. Lancet 376,328-329 (2010).
126. Yuji K, Matsumura T, Miyano S, Tsuchiya R, Kami M. Human papillomavirus vaccine coverage [letter]. Lancet 376, 329 (2010).
127. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch. Med. Res. 40(6), 478-485 (2009). Describes the need for a fundamental shift in the approach to screening given that the HPV vaccination program will reduce the prevalence of cervical abnormalities and thus the positive predictive value of cytology.
128. Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 337, a1754 (2008).
129. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26S, K29-K41 (2008).
130. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 26S, K42-K52 (2008).
131. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360, 1385-1394 (2009).
132. US Department of Health and Human Services, CDC, Office of the Director, Office of Strategy and Innovation. Introduction to Program Evaluation for Public Health Programs: A Self-Study Guide. CDC, Atlanta, GA, USA (2005).
133. Farmer P, Frenk J, Knaul FM et al. Expansion of cancer care and control in countries of low and middle income: A call to action. Lancet 376 (9747), 1186-1193 (2010).
134. Andrus JK, Sherris J, Fitzsimmons JW et al. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 26S, K87-K92 (2008).
135. Syrjänen KJ. Prophylactic HPV vaccines: The Finnish perspective. Expert Rev. Vaccines 9(1), 45-57 (2010).
136. McConnell D, Reid S, Turner N et al. Criticism of the decision not to fund the HPV vaccine for pre-adolescent females in New Zealand, and response. NZ Med. J. 120(1259), U2667 (2007).
137. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: An example from the U.S. Vaccine 25(48), 8110-8113 (2007). (Pubitemid 350046322)
138. Brotherton JML, Deeks SL, Campbell-Lloyd S et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun. Dis. Intell. 32, 457-461 (2008).